These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22760659)

  • 1. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
    Li CM; Lu Y; Chen J; Costello TA; Narayanan R; Dalton MN; Snyder LM; Ahn S; Li W; Miller DD; Dalton JT
    Pharm Res; 2012 Nov; 29(11):3053-63. PubMed ID: 22760659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1
    Wang Q; Arnst KE; Wang Y; Kumar G; Ma D; White SW; Miller DD; Li W; Li W
    J Med Chem; 2019 Jul; 62(14):6734-6750. PubMed ID: 31251599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
    Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W
    Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cytotoxic natural compound erianin binds to colchicine site of β-tubulin and overcomes taxane resistance.
    Yan W; Zhou Y; Yuan X; Bai P; Tang M; Chen L; Wei H; Yang J
    Bioorg Chem; 2024 Sep; 150():107569. PubMed ID: 38905886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
    Sampath D; Discafani CM; Loganzo F; Beyer C; Liu H; Tan X; Musto S; Annable T; Gallagher P; Rios C; Greenberger LM
    Mol Cancer Ther; 2003 Sep; 2(9):873-84. PubMed ID: 14555706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
    Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties.
    Wu JD; Cui YJ; Zhou YG; Tang LQ; Zhang CM; Liu ZP
    Invest New Drugs; 2020 Feb; 38(1):29-38. PubMed ID: 30887253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
    Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L
    Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
    Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
    Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
    Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
    Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
    Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M
    Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability.
    Li CM; Chen J; Lu Y; Narayanan R; Parke DN; Li W; Ahn S; Miller DD; Dalton JT
    Drug Metab Dispos; 2011 Oct; 39(10):1833-9. PubMed ID: 21742898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity.
    Bacher G; Nickel B; Emig P; Vanhoefer U; Seeber S; Shandra A; Klenner T; Beckers T
    Cancer Res; 2001 Jan; 61(1):392-9. PubMed ID: 11196193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
    Cai P; Lu P; Sharom FJ; Fang WS
    Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
    Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
    BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.
    Lee FY; Smykla R; Johnston K; Menard K; McGlinchey K; Peterson RW; Wiebesiek A; Vite G; Fairchild CR; Kramer R
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):201-12. PubMed ID: 18350296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microtubule Destabilizing Sulfonamides as an Alternative to Taxane-Based Chemotherapy.
    González M; Ovejero-Sánchez M; Vicente-Blázquez A; Álvarez R; Herrero AB; Medarde M; González-Sarmiento R; Peláez R
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer.
    Mahmud F; Deng S; Chen H; Miller DD; Li W
    Cancer Lett; 2020 Dec; 495():76-88. PubMed ID: 32920198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.